Miriam Aguti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miriam Aguti has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Harriet Adrama
Infectious Diseases Research Collaboration, Kampala, Uganda
4 shared publicationsJimmy Kizza
Infectious Diseases Research Collaboration (IDRC) , Kampala
4 shared publications- Prasanna Jagannathan
Stanford University
4 shared publications Peter Olwoch
Infectious Diseases Research Collaboration, Kampala, Uganda
3 shared publicationsPhilip J. Rosenthal
Department of Medicine, University of California, San Francisco, USA
3 shared publicationsAbel Kakuru
Infectious Diseases Research Collaboration, Kampala, Uganda
2 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Natural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Open AccessNatural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.
- Open Access
- 20 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e757-e765
Impact of Intermittent Preventive Treatment for Malaria in Pregnancy With Sulfadoxine-Pyrimethamine, Dihydroartemisinin-Piperaquine, and Their Combination on Infant Outcomes: A Randomized Controlled Trial
Background: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) is more effective than sulfadoxine-pyrimethamine (IPTp-SP) at reducing the burden of malaria in pregnancy. Paradoxically, IPTp-DP has been associated with lower birth weights compared with IPTp-SP. Whether the impacts of IPTp-DP extend after birth is unknown. Methods: We conducted a double-blind randomized controlled trial to compare malaria burden and growth among infants born to mothers who were randomized to monthly IPTp-SP, IPTp-DP, or IPTp-DP + SP. Infants were followed to 12 months of age by passive and active surveillance. The primary outcome was clinical malaria incidence; secondary outcomes included parasite prevalence and infant growth outcomes. Results: Among 871 infants enrolled, there were 667 episodes of clinical malaria. Compared to infants whose mothers received IPTp-SP, malaria incidence was similar in infants whose mothers received IPTp-DP (incidence rate ratio [IRR] 1.04, 95% CI .78–1.38) or IPTp-DP + SP (IRR = 0.93, 95% CI .68–1.26). Overall parasite prevalence at monthly visits was 21.8%. Parasite prevalence was also similar between groups. The prevalence of wasting at birth was higher in infants whose mothers received IPTp-DP + SP (prevalence ratio [PR] = 2.30, 95% CI 1.07–4.97) or IPTp-DP (PR = 2.25, 95% CI 1.03–4.94) than those that received IPTp-SP, but differences between groups resolved by 3–6 months of age. Conclusions: There were no significant differences in infant outcomes between the 3 IPTp arms apart from a transiently increased risk of wasting among infants born to mothers who received DP-containing IPTp regimens.
- 20 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e757-e765
Open AccessImpact of Intermittent Preventive Treatment for Malaria in Pregnancy With Sulfadoxine-Pyrimethamine, Dihydroartemisinin-Piperaquine, and Their Combination on Infant Outcomes: A Randomized Controlled Trial
Background: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) is more effective than sulfadoxine-pyrimethamine (IPTp-SP) at reducing the burden of malaria in pregnancy. Paradoxically, IPTp-DP has been associated with lower birth weights compared with IPTp-SP. Whether the impacts of IPTp-DP extend after birth is unknown. Methods: We conducted a double-blind randomized controlled trial to compare malaria burden and growth among infants born to mothers who were randomized to monthly IPTp-SP, IPTp-DP, or IPTp-DP + SP. Infants were followed to 12 months of age by passive and active surveillance. The primary outcome was clinical malaria incidence; secondary outcomes included parasite prevalence and infant growth outcomes. Results: Among 871 infants enrolled, there were 667 episodes of clinical malaria. Compared to infants whose mothers received IPTp-SP, malaria incidence was similar in infants whose mothers received IPTp-DP (incidence rate ratio [IRR] 1.04, 95% CI .78–1.38) or IPTp-DP + SP (IRR = 0.93, 95% CI .68–1.26). Overall parasite prevalence at monthly visits was 21.8%. Parasite prevalence was also similar between groups. The prevalence of wasting at birth was higher in infants whose mothers received IPTp-DP + SP (prevalence ratio [PR] = 2.30, 95% CI 1.07–4.97) or IPTp-DP (PR = 2.25, 95% CI 1.03–4.94) than those that received IPTp-SP, but differences between groups resolved by 3–6 months of age. Conclusions: There were no significant differences in infant outcomes between the 3 IPTp arms apart from a transiently increased risk of wasting among infants born to mothers who received DP-containing IPTp regimens.
- Open Access
- 30 December 2025
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Maternal and household risk factors for malaria in pregnancy and low birthweight: a prospective cohort study from Uganda
Malaria is a leading cause of illness and death in pregnant women and newborns. In 2023, an estimated 12.4 million pregnant women were infected with malari
- 30 December 2025
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Open AccessMaternal and household risk factors for malaria in pregnancy and low birthweight: a prospective cohort study from Uganda
Malaria is a leading cause of illness and death in pregnant women and newborns. In 2023, an estimated 12.4 million pregnant women were infected with malari
- Open Access
The Natural History and Burden of Malaria During the First Year of Life in a High Transmission Setting in Uganda
Infants under one year of age are considered partially protected from malaria due to maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that malaria burden in this age group may be underestimated. We enrolled a cohort of 855 infants in Busia District, Uganda to characterize and identify risk factors for malaria incidence and parasite prevalence during the first year of life. The study was conducted from 2021-2025, prior to malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4-8 weeks of age and followed 7 days/week in a dedicated study clinic to 1 year of age. Routine visits every 4 weeks included assessments for parasitemia by microscopy and quantitative PCR. Over 706.7 person-years of follow-up, 662 malaria episodes occurred; 71% occurred prior to 9 months of age. Overall prevalence of microscopic parasitemia was 7.9% and combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (HbAS) conferred 39% protection against symptomatic malaria but had no association with risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of alpha-cypermethrin plus chlorfenapyr long-lasting insecticide-treated nets in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventive interventions targeting young infants, such as earlier vaccine administration and/or monoclonal antibodies, alongside sustained investment in next-generation vector control, and attention to socioeconomic determinants of malaria risk.
Open AccessThe Natural History and Burden of Malaria During the First Year of Life in a High Transmission Setting in Uganda
Infants under one year of age are considered partially protected from malaria due to maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that malaria burden in this age group may be underestimated. We enrolled a cohort of 855 infants in Busia District, Uganda to characterize and identify risk factors for malaria incidence and parasite prevalence during the first year of life. The study was conducted from 2021-2025, prior to malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4-8 weeks of age and followed 7 days/week in a dedicated study clinic to 1 year of age. Routine visits every 4 weeks included assessments for parasitemia by microscopy and quantitative PCR. Over 706.7 person-years of follow-up, 662 malaria episodes occurred; 71% occurred prior to 9 months of age. Overall prevalence of microscopic parasitemia was 7.9% and combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (HbAS) conferred 39% protection against symptomatic malaria but had no association with risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of alpha-cypermethrin plus chlorfenapyr long-lasting insecticide-treated nets in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventive interventions targeting young infants, such as earlier vaccine administration and/or monoclonal antibodies, alongside sustained investment in next-generation vector control, and attention to socioeconomic determinants of malaria risk.